A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects-Reference-Cited by-同舟云学术

A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects

Published:2011-12-14 Issue:3 Volume:131 Page:E304-E311
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Abbas Richat,Hug Bruce A.,Leister Cathie,Sonnichsen Daryl

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference24 articles.

1. ICH E14 Guidance: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs;Federal Register,2005

2. Cardiac repolarization and the safety of new drugs defined by electrocardiography;Morganroth;Clin Pharmacol Ther,2007

3. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death;Glassman;Am J Psychiatry,2001

4. The significance of QT interval in drug development;Shah;Br J Clin Pharmacol,2002

5. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development;Curigliano;Eur J Cancer,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques);Bulletin du Cancer;2024-01

2. Recommendations on the use of azole antifungals in hematology-oncology patients;Revista Española de Quimioterapia;2023-04-05

3. Torsades de pointes in patients with cancer;Torsades de Pointes;2022

4. Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development;Clinical and Translational Science;2019-10-31

5. The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors;Cancer Chemotherapy and Pharmacology;2019-06-11